全文获取类型
收费全文 | 1405篇 |
免费 | 67篇 |
国内免费 | 82篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 67篇 |
妇产科学 | 9篇 |
基础医学 | 146篇 |
口腔科学 | 24篇 |
临床医学 | 228篇 |
内科学 | 303篇 |
皮肤病学 | 41篇 |
神经病学 | 30篇 |
特种医学 | 317篇 |
外科学 | 64篇 |
综合类 | 26篇 |
预防医学 | 118篇 |
眼科学 | 6篇 |
药学 | 108篇 |
肿瘤学 | 65篇 |
出版年
2022年 | 5篇 |
2021年 | 9篇 |
2019年 | 12篇 |
2018年 | 7篇 |
2017年 | 9篇 |
2016年 | 11篇 |
2015年 | 18篇 |
2014年 | 11篇 |
2013年 | 28篇 |
2012年 | 12篇 |
2011年 | 16篇 |
2010年 | 49篇 |
2009年 | 48篇 |
2008年 | 19篇 |
2007年 | 56篇 |
2006年 | 19篇 |
2005年 | 27篇 |
2004年 | 12篇 |
2003年 | 16篇 |
2002年 | 27篇 |
2001年 | 19篇 |
2000年 | 25篇 |
1999年 | 32篇 |
1998年 | 95篇 |
1997年 | 91篇 |
1996年 | 112篇 |
1995年 | 87篇 |
1994年 | 93篇 |
1993年 | 79篇 |
1992年 | 37篇 |
1991年 | 42篇 |
1990年 | 30篇 |
1989年 | 37篇 |
1988年 | 43篇 |
1987年 | 36篇 |
1986年 | 36篇 |
1985年 | 37篇 |
1984年 | 17篇 |
1983年 | 25篇 |
1982年 | 22篇 |
1981年 | 25篇 |
1980年 | 23篇 |
1979年 | 10篇 |
1978年 | 17篇 |
1977年 | 17篇 |
1976年 | 17篇 |
1975年 | 10篇 |
1974年 | 7篇 |
1973年 | 5篇 |
1969年 | 3篇 |
排序方式: 共有1554条查询结果,搜索用时 15 毫秒
1.
2.
3.
The tetracyclines in dermatology. 总被引:5,自引:0,他引:5
P Humbert P Treffel J F Chapuis S Buchet C Derancourt P Agache 《Journal of the American Academy of Dermatology》1991,25(4):691-697
Tetracycline is one of the most widely used antibiotics. It may share some properties with conventional immunosuppressive drugs and act as an anti-inflammatory agent in the treatment of inflammatory disease. This article reviews cutaneous diseases that have been treated with tetracyclines and their antiinflammatory and immunosuppressive properties. 相似文献
4.
5.
6.
H A Roels R R Lauwerys J P Buchet A M Bernard P Lijnen G Van Houte 《British journal of industrial medicine》1990,47(5):331-337
A significant reduction of kallikrein activity in urine (assayed by its amidolytic activity) was found in 64 normotensive workers who had been exposed to cadmium for 11 years on average and whose cadmium concentrations in urine ranged from 2.2 to 33.1 micrograms/g creatinine. The mean (geometric) urinary kallikrein activity (in U/g creatinine) amounted to 0.52 (range 0.11-1.90) in the control group (n = 193) against 0.39 (range 0.10-1.03) in the cadmium group, and the prevalence of abnormally low activity levels (less than or equal to 0.20 U/g creatinine) amounted to 17.2% in the cadmium group against 5.2% in the control group. A reduction of aldosterone release (aldosterone in urine) associated with an increased natriuresis was also observed. This might constitute a compensatory mechanism maintaining blood pressure in the normal range. These biological effects of cadmium were not reversible after removal from exposure. This study indicates that cadmium can induce an irreversible toxic effect in the distal nephron. It also suggests that an excessive cadmium body burden alone may not be sufficient to induce hypertension, but in individuals whose blood pressure regulation may be impaired by other factors cadmium could stimulate the development of hypertension. This study also supports the recommendation to prevent hypertensive subjects from being exposed to cadmium. There was no indication that moderate exposure to mercury vapour (n = 53; mercury in urine, range 11-224 micrograms/g creatinine; average duration of exposure: six years) or to inorganic lead (n = 23; lead in blood, range 40-67 micrograms/100 ml; average duration of exposure: eight years) was associated with a reduction of kallikrein production by the kidney. 相似文献
7.
8.
J Staessen A Bernard J P Buchet F Claeys L Dekempeneer G Ducoffre R Fagard R Lauwerys P Lijnen H Roels 《IARC scientific publications》1992,(118):263-269
This paper summarizes the findings of the Cadmibel Study, a cross-sectional population study of the health effects of cadmium, but only with respect to the cardiovascular system and calcium metabolism. The study disproved the hypothesis that exposure to cadmium would lead to an increase in blood pressure and in the prevalence of hypertension and other cardiovascular diseases. On the other hand, there was a positive relationship between urinary cadmium (Cd-U) and both serum alkaline phosphatase activity and urinary excretion of calcium. The regression coefficients obtained after adjustment for significant co-variates indicated that, when Cd-U increased two-fold, serum alkaline phosphatase and urinary calcium rose by 4% and 0.25 mmol/24 h, respectively. These findings suggest that calcium metabolism is gradually affected as cadmium accumulates in the body. The morbidity associated with the latter phenomenon is still unknown, and requires further investigation, preferably in a longitudinal prospective population study, in which the incidence of morbid events would be monitored in relation to the cadmium body burden. 相似文献
9.
10.
Y Leskinen JP Salenius T Lehtim?ki H Huhtala H Saha 《American journal of kidney diseases》2002,40(3):472-479
BACKGROUND: Knowledge of the prevalence of peripheral arterial disease (PAD) in patients with chronic renal failure (CRF) is limited because of a lack of uniformity in disease definition and recognition. Furthermore, little is known of the prevalence of medial arterial calcification (MAC) in patients with CRF. Our goal is to study the prevalence of PAD and MAC defined by ankle brachial index (ABI) or toe brachial index (TBI) measurements in a Finnish population of patients with CRF consisting of predialysis and dialysis patients, as well as renal transplant recipients. METHODS: We examined 136 patients with CRF and 59 control subjects. Fifty-nine of the patients with CRF had moderate to severe predialysis CRF, 36 patients were on dialysis treatment, and 41 were renal transplant recipients. Mean age of patients was 51.9 +/- 11.5 years, and 39 patients (29%) had diabetes. ABI and TBI were measured by means of photoplethysmography. The definition of PAD required an ABI value of 0.90 or less, a TBI value of 0.60 or less, or a previous positive lower-extremity angiogram result. ABI values of 1.3 or greater or incompressible arteries at ankle level indicated MAC. The presence of claudication was determined by an interview. RESULTS: Prevalences of PAD on this study were 22.0% in patients with predialysis CRF, 30.6% in patients on dialysis treatment, 14.6% in renal transplant recipients, and 1.7% in the control group (P = 0.001). Prevalences of MAC were 23.7%, 41.7%, 23.1%, and 3.4% (P < 0.001), respectively. Only 9 patients had claudication, and 6 of those patients had PAD. CONCLUSION: Both asymptomatic PAD and MAC are common in patients with CRF. Therefore, we recommend the use of both ABI and TBI measurements in the evaluation of PAD in patients with CRF. 相似文献